Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 11/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7642781 | 1.00 | CA1 (0.46) | CA1CA2CA7TDP1CTSK | |
| SCHEMBL2617386 | 1.00 | CA1 (0.46) | CA1CA2CA7TDP1CTSK | |
| SCHEMBL3735437 | 0.92 | CA1 (0.49) | CA1CA2CA7TDP1CTSK | |
| SCHEMBL28323890 | 0.89 | TDP1 (0.49) | CA1CA2CA7TDP1CTSK | |
| SCHEMBL2296899 | 0.89 | TDP1 (0.49) | CA1CA2CA7TDP1CTSK | |
| SCHEMBL2296898 | 0.89 | TDP1 (0.49) | CA1CA2CA7TDP1CTSK | |
| SCHEMBL2861782 | 0.88 | CA1 (0.52) | CA1CA2CA7TDP1CTSK | |
| SCHEMBL13040189 | 0.88 | TDP1 (0.51) | CA1CA2CA7TDP1CTSK | |
| SCHEMBL8042680 | 0.88 | TDP1 (0.51) | CA1CA2CA7TDP1CTSK | |
| SCHEMBL24298350 | 0.87 | CA1 (0.45) | CA1CA2CA7TDP1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107759779-B | Antibacterial polyester material and preparation method thereof | 东华大学 | 2020-04-07 | — | — | CN | claimed |
| US-20240156965-A1 | DICHALCOGENIDE PRODRUGS | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2024-05-16 | — | — | US | disclosed |
| CN-112638898-B | Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors | 泽农医药公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4320124-A1 | DICHALCOGENIDE PRODRUGS | Ludwig-Maximilians-Universität München (DE) | 2024-02-14 | — | — | EP | disclosed |
| US-11555051-B2 | Dithioamine reducing agents | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-01-17 | — | — | US | disclosed |
| WO-2022214598-A1 | DICHALCOGENIDE PRODRUGS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2022-10-13 | — | — | WO | disclosed |
| EP-4071148-A1 | DICHALCOGENIDE PRODRUGS | Ludwig-Maximilians-Universität München (DE) | 2022-10-12 | — | — | EP | disclosed |
| CN-109526219-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20190153025-A1 | Dithioamine Reducing Agents | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2019-05-23 | — | — | US | disclosed |
| US-20150307544-A1 | DITHIOAMINE REDUCING AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-29 | — | — | US | disclosed |
| US-9090662-B2 | Dithioamine reducing agents | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-20130211055-A1 | DITHIOAMINE REDUCING AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-08-15 | — | — | US | disclosed |
| US-6472533-B1 | SUCH AS PHOSPHINE OXAZOLINES; HIGH ENANTIOSELECTIVITY; CATALYSTS FOR SYNTHESIS OF ACTIVE MATERIALS FOR PHARMACEU-TICALS, AGROCHEMICALS, FRAGRANCES AND FOOD ADDITIVES; EFFICIENT | THE TEXAS A & M UNIVERSITY SYSTEM | 2002-10-29 | — | — | US | disclosed |
| CN-1353718-A | Novel ligands for chiral catalysis | TEXAS A & M UNIV SYS (US) | 2002-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307544-A1 | DITHIOAMINE REDUCING AGENTS | TMT1A, QSOX1, TST | CA1 1886/4885CA2 2090/4885CA7 3951/4885 |
| US-20190153025-A1 | Dithioamine Reducing Agents | TMT1A, QSOX1, TST | CA1 1886/4885CA2 2090/4885CA7 3951/4885 |
| US-20240156965-A1 | DICHALCOGENIDE PRODRUGS | DHCR7, DECR1, CYP27A1 | CA1 179/4885CA2 864/4885CA7 381/4885 |
| US-11555051-B2 | Dithioamine reducing agents | TMT1A, QSOX1, TST | CA1 1886/4885CA2 2090/4885CA7 3951/4885 |
| US-20130211055-A1 | DITHIOAMINE REDUCING AGENTS | SQOR, TST, TMT1A | CA1 1006/4885CA2 1282/4885CA7 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.